Hemab Therapeutics said Monday it has launched an initial public offering of about 11.8 million shares of common stock, with pricing estimated to be between $16 and $18 per share.

The company granted underwriters the option to purchase up to an additional 1.8 million shares at the initial public offering price.

Net proceeds from the offering will be used to initiate a planned phase 3 clinical trial of sutacimig in Glanzmann thrombasthenia and report data from a phase 2 clinical trial of sutacimig in Factor VII deficiency, among others, the company said.

Hemab Therapeutics said it has applied to list its common stock on Nasdaq under the symbol "COAG."